2025-05-15T10:59:44-05:00 2024-12-31 450250958 EIDE BAILLY LLP 5 TRIAD CENTER STE 600 SALT LAKE CITY UT 841801106 990 2024-01-01 831246927 CIVICA INC CIVI 8883040120 2912 W EXECUTIVE PKWY STE 325 LEHI UT 84043 EAMON FITZMAURICE CHIEF FINANCIAL OFFICER 8883040120 2025-05-15 1 1 KYLE FRITCH CPA P01313374 8015322200 2025-05-15 2024 2025-03-06 01:10:19Z CIVICARX NED MCCOY 2912 W EXECUTIVE PKWY STE 325 LEHI UT 84043 151792726 0 X WWW.CIVICARX.ORG X 2018 DE ALLEVIATE SUPPLY SHORTAGES FOR ESSENTIAL GENERIC MEDICATIONS AND ENSURE AFFORDABILITY FOR EVERYONE. 15 14 293 14 0 0 7301609 28432107 4426613 5439790 1036174 2226750 37903903 28893955 50668299 64992602 0 0 0 0 37799565 49384379 0 0 0 59153696 63840163 96953261 113224542 -46284962 -48231940 236715779 283067991 209136913 303721065 27578866 -20653074 X CIVICA'S MISSION IS TO ENHANCE AVAILABILITY AND AFFORDABILITY OF QUALITY GENERIC INJECTABLES FOR PATIENTS, ESPECIALLY HIGH NEEDS POPULATIONS, BY (1) ALLEVIATING DRUG SHORTAGES AND (2) PROVIDING THESE DRUGS AT A SUSTAINABLE AND AFFORDABLE LEVEL, BOTH VIA ITS MEMBER HOSPITAL SYSTEMS AS WELL AS NON-MEMBER ORGANIZATIONS INCLUDING NON-MEMBER COVERED ENTITIES LIKE 340B HOSPITALS AND ADDITIONALLY, GOVERNMENT ORGANIZATIONS INCLUDING VETERANS AFFAIRS AND DEPARTMENT OF DEFENSE. 1 0 36894776 31500392 GENERIC DRUG DISTRIBUTIONDEVELOP AN OPEN AND GROWING NETWORK OF HOSPITALS TO EXPAND THE REACH OF CIVICA'S MISSION AND ITS BENEFITS TO BOTH MEMBERS AND NON-MEMBERS. ALLEVIATE SHORTAGES OF ESSENTIAL DRUG PRODUCTS AND STABILIZE PRICING BY SECURING AVAILABILITY FROM EXISTING MANUFACTURERS FOR THE BENEFIT OF PATIENTS SERVED BY THESE MEMBERS AND NON-MEMBER CUSTOMERS. CIVICA'S MAJOR ACCOMPLISHMENTS TO DATE INCLUDE THE FOLLOWING:(1) CONTINUED CUSTOMER GROWTH WITH 85 MILLION PATIENTS SERVED TO DATE. NEW CUSTOMERS ENROLLED INCLUDE NATIONWIDE NON-MEMBER 340B HOSPITALS THAT SERVE A DISPROPORTIONATE POPULATION OF HIGH-NEED PATIENTS, VETERANS AFFAIRS HOSPITALS, AND THE DEPARTMENT OF DEFENSE. (2) CONTINUED LAUNCH OF ESSENTIAL MEDICINES DEEMED IN SHORT SUPPLY PER THE FDA OR ASHP DRUG SHORTAGES LISTS.(3) ESTABLISHED AND MAINTAINED APPROXIMATELY 6 MONTHS OF FINISHED GOODS INVENTORY TO BUFFER ANY SUPPLY CHAIN SHOCKS TYPICALLY EXPERIENCED IN THE INDUSTRY FOR ESSENTIAL STERILE INJECTABLE MEDICINES. (4) SINGLE TRANSPARENT AFFORDABLE PRICING TO ALL MEMBERS AND NON-MEMBERS REGARDLESS OF MEMBERSHIP STATUS, SIZE OF THE HOSPITAL, VOLUME OF DRUGS PURCHASED FROM CIVICA OR RELATIONSHIP LONGEVITY WITH CIVICA. 48851416 FILL - FINISH FACILITYTHE COVID-19 PANDEMIC, WHICH RESULTED IN A SPIKE IN DEMAND FOR MEDICATIONS IN HOSPITALS MANAGING SIGNIFICANT PATIENT SURGES, BROUGHT TO LIGHT THE DEPENDENCE OF THE UNITED STATES ON FOREIGN MANUFACTURERS OF GENERIC, ESSENTIAL, LIFE-SAVING MEDICATIONS; ESPECIALLY STERILE INJECTABLES. IN AN EFFORT TO ON-SHORE END-TO-END MANUFACTURING OF SUCH STERILE INJECTABLES, AND AS A NATIONAL SECURITY MEASURE, BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY ("BARDA"), A U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ("HHS") GOVERNMENT OFFICE RESPONSIBLE FOR THE PROCUREMENT AND DEVELOPMENT OF MEDICAL COUNTERMEASURES, PRINCIPALLY AGAINST BIOTERRORISM, INCLUDING CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR THREATS, AS WELL AS PANDEMIC INFLUENZA AND EMERGING DISEASES, AWARDED CONTRACT NO. 75A50120C00092 ("PRIME CONTRACT") TO PHLOW CORP., ("PHLOW") TO CREATE END-TO-END MANUFACTURING IN THE UNITED STATES. PHLOW IS A DELAWARE PUBLIC BENEFIT CORPORATION ENGAGED IN THE BUSINESS OF THE RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION OF PHARMACEUTICAL PRODUCTS. PHLOW SUBCONTRACTED CERTAIN OF ITS OBLIGATIONS UNDER THE PRIME CONTRACT TO CIVICA WHEREBY CIVICA WILL QUALIFY, DESIGN, BUILD, EQUIP, OPERATE, AND OWN A 120,000 SQUARE FOOT, TWO-STORY, CGMP COMPLIANT ASEPTIC FILL-FINISH FACILITY ("FILL-FINISH FACILITY"), TO BE FUNDED, AT LEAST PARTIALLY, WITH $100,000,000 PROVIDED BY BARDA. THE FILL-FINISH FACILITY WILL BE CAPABLE OF, AMONG OTHER THINGS, PROVIDING AT LEAST 90 MILLION ASEPTIC OR TERMINALLY STERILIZED VIALS AND 50 MILLION PRE-FILLED SYRINGES ANNUALLY. THE FACILITY IS COMPLETE ALONG WITH SUBMISSION OF THE APPLICATION FOR THE APPROVAL OF THE FACILITY. THE FIRST PRODUCTS, AND COMMENCEMENT OF COMMERCIAL PRODUCTION, ARE ANTICIPATED IN 2026. CIVICA INTENDS TO USE THE FILL-FINISH FACILITY TO, AMONG OTHER THINGS, (1) MANUFACTURE STERILE INJECTABLES IN FURTHERANCE OF ITS GENERIC DRUG DISTRIBUTION PROGRAM IDENTIFIED PREVIOUSLY, (2) SUPPORT THE NEEDS OF THE U.S. GOVERNMENT FOR ANY FUTURE PANDEMICS OR SIMILAR EMERGENCIES, (3) PROVIDE SURPLUS MANUFACTURING CAPACITY TO OTHER U.S.-BASED STERILE INJECTABLE MANUFACTURERS WHO SERVE THE NEEDS OF THE COUNTRY FOR SHORTAGE MEDICATIONS, AND (4) PRODUCE LOW-COST INSULIN FOR THE US MARKET TO ALLEVIATE DISTRESS THAT AFFORDABILITY CHALLENGES CAUSE TO PATIENTS. 1210295 1210295 OUT-PATIENT SERVICESON OR ABOUT JANUARY 23, 2020, CIVICA ANNOUNCED AN ARRANGEMENT WITH THE BLUE CROSS BLUE SHIELD ASSOCIATION ("BCBSA") AND A NUMBER OF INDEPENDENT BLUE CROSS AND BLUE SHIELD COMPANIES ("BCBSS; WITH BCBSA, THE "BLUES"). THE ARRANGEMENT INVOLVED THE CREATION OF A NEW BUSINESS ENTITY, CIVICASCRIPT, DEDICATED TO LOWERING THE COST OF SELECT OUTPATIENT GENERIC MEDICATIONS IN RESPONSE TO THE IMPACT OF HIGH DRUG COSTS ON THE HEALTH OF AMERICANS AND THE OVERALL AFFORDABILITY OF HEALTH CARE BY DEVELOPING AND MANUFACTURING GENERIC OUTPATIENT MEDICATIONS. IN FURTHERANCE OF THE ARRANGEMENT, ON OR ABOUT JANUARY 27, 2020, CIVICA CAUSED CIVICASCRIPT TO BE ORGANIZED AS A DELAWARE LIMITED LIABILITY COMPANY TO PROMOTE PUBLIC BENEFITS, INCLUDING PROMOTION OF AVAILABILITY OF AFFORDABLE OUTPATIENT GENERIC DRUGS. CIVICASCRIPT, A STATUTORY PUBLIC BENEFIT LLC UNDER DELAWARE LAW , IS TREATED AS A CORPORATION FOR U.S FEDERAL TAX PURPOSES. HOWEVER, CIVICASCRIPT HAS APPLIED FOR TAX-EXEMPT STATUS AS A PUBLIC CHARITY. IF APPROVED, THE EFFECTIVE DATE OF EXEMPTION WOULD BE SEPTEMBER 1, 2023.BASED ON MARKET AND OTHER RESEARCH BY CIVICASCRIPT, AS APPROVED BY ITS BOARD, CIVICASCRIPT IS CURRENTLY IN THE PROCESS OF DEVELOPING GENERIC VERSIONS OF CERTAIN MEDICATIONS. IN ALIGNMENT WITH CIVICASCRIPT'S FOUNDING MISSION, THESE GENERIC MEDICATIONS WILL BE SOLD TO CIVICA-AFFILIATED HOSPITALS, ALL "340B HOSPITALS,", ALL VETERANS AFFAIRS ("VA") HOSPITALS, AND TO RETAILERS.CIVICA, INC. ENTERED INTO A SERVICES AGREEMENT EFFECTIVE SEPTEMBER 1, 2020, WITH CIVICASCRIPT. CIVICA, INC. IS A MEMBER OF CIVICASCRIPT AND A RELATED PARTY. THE PROVISIONS OF THIS AGREEMENT ALLOW FOR CIVICA, INC. TO PROVIDE CIVICASCRIPT WITH ADMINISTRATIVE SUPPORT AND OTHER SERVICES TO ENABLE THE PUBLIC TO REALIZE THE BENEFITS CIVICASCRIPT INTENDS TO PROVIDE. THESE SERVICES INCLUDE EXECUTIVE MANAGEMENT SERVICES, PROFESSIONAL ASSISTANCE, RISK MANAGEMENT, QUALITY & REGULATORY SUPPORT AND OVERSIGHT, FINANCE & ACCOUNTING SERVICES, AND DATA ANALYTICS. 385798 1623058 CIVICA ENTERED INTO A MASTER SERVICE AGREEMENT WITH A US BASED FOR PROFIT PHARMA COMPANY ON APRIL 18, 2024, TO SUPPORT THE GLOBAL SUPPLY OF (FILL AND FINISH) STERILE INJECTABLE MEDICATIONS WHICH WERE ON THE FDA DRUG SHORTAGE LIST, AND FOR WHICH THE PARTNERING COMPANY IS DELAYING LAUNCHES IN MARKETS DUE TO PRODUCTION CAPACITY CONSTRAINTS. PURSUANT TO WORK ORDERS UNDER THIS AGREEMENT, CIVICA IS PRODUCING BOTH PRE-FILLED SYRINGES AND CARTRIDGES FOR ASSEMBLY INTO INJECTION DEVICES. THIS PROGRAM ADVANCES CIVICA'S MISSION TO INCREASE ACCESS TO ESSENTIAL, AFFORDABLE MEDICATIONS BY SUPPORTING A LOW-COST, RELIABLE PRODUCTION OF HIGH-DEMAND, CLINICALLY IMPORTANT TREATMENTS FOR PATIENTS. 385798 1623058 87342285 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 72 0 1 293 1 0 0 0 0 1 1 0 0 0 X 15 14 0 0 0 0 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 0 UT X JENNIFER SPALDING 8883040120 2912 W EXECUTIVE PARKWAY STE 325 LEHI UT 84043 X NED MCCOY CHIEF EXECUTIVE OFFICER 24.00 16.00 X X 790906 527270 48984 DAN LILJENQUIST CHAIR 2.00 3.00 X X 0 0 0 DENNIS DAHLEN DIRECTOR 1.00 0.00 X 0 0 0 SHELLEY LYFORD DIRECTOR 1.00 2.00 X 0 0 0 KATHLEEN SANFORD DIRECTOR 1.00 0.00 X 0 0 0 ANDREA NODA DIRECTOR 1.00 0.00 X 0 0 0 ERIN ASPREC DIRECTOR 1.00 0.00 X 0 0 0 WILLIAM RUTHERFORD DIRECTOR (THRU APRIL '24) 1.00 0.00 X 0 0 0 MICHAEL ROWE DIRECTOR (THRU AUG. '24) 1.00 0.00 X 0 0 0 DREW HOBBY DIRECTOR 1.00 0.00 X 0 0 0 DAN ROTH DIRECTOR 1.00 0.00 X 0 0 0 HODA ASMAR DIRECTOR 1.00 0.00 X 0 0 0 MAIRIN MANCINO DIRECTOR 1.00 0.00 X 0 0 0 DAVID YODER DIRECTOR 1.00 1.00 X 0 0 0 JOHN HACKETT DIRECTOR (FROM MAY '24) 1.00 0.00 X 0 0 0 KEVIN SMITH DIRECTOR (FROM NOV. '24) 1.00 0.00 X 0 0 0 CHRIS CLAGG DIRECTOR (FROM AUG. '24) 1.00 0.00 X 0 0 0 JENNIFER SPALDING CHIEF COMM'L OFFICER/GENERAL COUNSEL 26.00 14.00 X 583770 314337 31196 EAMON FITZMAURICE CHIEF FINANCIAL OFFICER 24.00 16.00 X 534964 356643 52140 DEBBI FORD CHIEF COMMUNICATIONS (THRU OCT '24) 16.00 24.00 X 323909 485863 48813 DONNA GULBINSKI CHIEF QUALITY & REG AFFAIRS OFFICER 28.00 12.00 X 621572 266388 55759 KRISTOPHER WEIDLING CHIEF HUMAN RESOURCES 36.00 4.00 X 796605 88512 65526 JAY BENSON CHIEF MFG & SUPPLY CHAIN OFFICER 36.00 4.00 X 628559 69840 64876 ALLAN COUKELL CHIEF GOVT. AFFAIRS/PUBLIC POLICY OFFICER 30.00 10.00 X 406420 135474 64653 4686705 2244327 431947 115 0 1 0 GRONINGER USA LLC 14045 SOUTH LAKES DRIVE CHARLOTTE NC 28273 EQUIPMENT MACHINING 1010801 BLACK DIAMOND NETWORKS LLC 32 MAIN ST ANDOVER MA 01810 PROFESSIONAL SERVICES 546799 BIOTHERMAL VALIDATION LLC 5217 TANGLEWILD DR RALEIGH NC 27613 VALIDATION SERVICES 440410 AAYUNTRA LLC 110 TINKER IRVINE CA 92618 PROFESSIONAL SERVICES 430818 BUCHANAN INGERSOLL & ROONEY PC 501 GRANT STREET STE 200 PITTSBURGH PA 15219 LEGAL SERVICES 398393 13 27923957 233550 274600 28432107 SERVICES TO CIVICASCRIPT 561499 5439790 5439790 5439790 2226750 2226750 115694079 86800124 28893955 28893955 64992602 34333745 0 2226750 X 1992059 1653409 338650 39111074 32437900 6673174 804062 666880 137182 5409011 4486242 922769 2068173 1715359 352814 762527 617356 145171 218954 177269 41685 11362666 9199430 2163236 327448 327448 392187 323549 68638 2387374 1969555 417819 1411714 1245728 165986 1302042 969890 332152 967212 720475 246737 11346819 11346819 123127 80506 42621 1237163 856691 380472 SELLING EXPENSES 11938534 11938534 STARTUP COSTS 9692824 9692824 OTHER EXPENSE 3854067 3124539 729528 RESEARCH AND DEVELOPMEN 3445589 3445589 3069916 1693112 1376804 113224542 87342285 25882257 0 20367715 36440645 17504398 13255107 34137726 30468707 722963 1153621 193574853 609697 159165989 192965156 4816988 8784755 236715779 283067991 28320870 64914522 180368513 236705682 447530 2100861 209136913 303721065 X -72421134 -120653074 100000000 100000000 27578866 -20653074 236715779 283067991 -48231940 0 X 0 1 X 1 0 76588501 76588501 13117 13117 0 65893015 596580 65296435 51080220 51080220 192965156 DEFERRED COMPENSATION LIABILITY 208244 OPERATING LEASE LIABILTY 1892617 2100861 X PART X, LINE 2: THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AFFECTING ITS ANNUAL FILING REQUIREMENTS AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. THE ORGANIZATION WOULD RECOGNIZE FUTURE ACCRUED INTEREST AND PENALTIES RELATED TO UNRECOGNIZED TAX BENEFITS AND LIABILITIES IN INCOME TAX EXPENSE IF SUCH INTEREST AND PENALTIES ARE INCURRED. 1 X X X X X 0 0 0 0 0 0 0 1 0 NED MCCOY CHIEF EXECUTIVE OFFICER 389446 259630 401460 267640 0 0 8280 5520 21844 14563 821030 547353 0 0 KRISTOPHER WEIDLING CHIEF HUMAN RESOURCES 367080 40787 429525 47725 0 0 12342 1371 47321 5258 856268 95141 0 0 DONNA GULBINSKI CHIEF QUALITY & REG AFFAIRS OFFICER 287497 123213 334075 143175 0 0 9660 4140 30205 12945 661437 283473 0 0 EAMON FITZMAURICE CHIEF FINANCIAL OFFICER 248614 165743 286350 190900 0 0 8280 5520 23470 15647 566714 377810 0 0 JENNIFER SPALDING CHIEF COMM'L OFFICER/GENERAL COUNSEL 273556 147299 310214 167038 0 0 8970 4830 11577 6234 604317 325401 0 0 DEBBI FORD CHIEF COMMUNICATIONS (THRU OCT '24) 133009 199513 190900 286350 0 0 5362 8043 14405 21608 343676 515514 0 0 JAY BENSON CHIEF MFG & SUPPLY CHAIN OFFICER 368548 40950 260011 28890 0 0 12420 1380 46342 5149 687321 76369 0 0 ALLAN COUKELL CHIEF GOVT. AFFAIRS/PUBLIC POLICY OF 277394 92465 129026 43009 0 0 10350 3450 38722 12907 455492 151831 0 0 PART I, LINE 7 THERE ARE DISCRETIONARY BONUSES THAT ARE AWARDED AND DETERMINED BY THE COMPENSATION COMMITTEE. THE BONUSES ARE BASED UPON OVERALL BUSINESS ACCOMPLISHMENTS COMPARED TO THE GOALS SET BY THE ORGANIZATION. FORM 990, PART III, LINE 2 CIVICA ENTERED INTO A MASTER SERVICE AGREEMENT WITH A US BASED FOR PROFIT PHARMA COMPANY ON APRIL 18, 2024, TO SUPPORT THE GLOBAL SUPPLY OF (FILL AND FINISH) STERILE INJECTABLE MEDICATIONS WHICH WERE ON THE FDA DRUG SHORTAGE LIST, AND FOR WHICH THE PARTNERING COMPANY IS DELAYING LAUNCHES IN MARKETS DUE TO PRODUCTION CAPACITY CONSTRAINTS. PURSUANT TO WORK ORDERS UNDER THIS AGREEMENT, CIVICA IS PRODUCING BOTH PRE-FILLED SYRINGES AND CARTRIDGES FOR ASSEMBLY INTO INJECTION DEVICES. THIS PROGRAM ADVANCES CIVICA'S MISSION TO INCREASE ACCESS TO ESSENTIAL, AFFORDABLE MEDICATIONS BY SUPPORTING A LOW-COST, RELIABLE PRODUCTION OF HIGH-DEMAND, CLINICALLY IMPORTANT TREATMENTS FOR PATIENTS. FORM 990, PART VI, SECTION A, LINE 6 CIVICA, INC. HAS ONE CLASS OF MEMBERS. FORM 990, PART VI, SECTION A, LINE 7A EACH GOVERNING MEMBER HAS THE RIGHT TO NOMINATE ONE INDIVIDUAL TO SERVE ON CIVICA'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B THE GOVERNING DOCUMENTS REQUIRE THE APPROVAL OF TWO-THIRDS OF THE GOVERNING MEMBERS FOR THE: I) FORMATION OF AND DELEGATION OF ANY POWER BY THE BOARD OF DIRECTORS TO AN EXECUTIVE COMMITTEE OR ANY SIMILAR COMMITTEE; II) AMENDMENT OR RESTATEMENT OF THE ARTICLES OF INCORPORATIONS EXCEPT IN CERTAIN LIMITED CIRCUMSTANCES WHERE APPROVAL OF 100% OF THE GOVERNING MEMBERS IS REQUIRED, AND III) AMENDMENT OR RESTATEMENT OF THE BYLAWS. THE GOVERNING DOCUMENTS ALSO REQUIRE APPROVAL BY 90% OF ALL OF THE GOVERNING MEMBERS FOR I) CHANGING THE STRATEGIC LINES OF BUSINESS OF THE ORGANIZATION; II) DISPOSING OF ALL OR SUBSTANTIALLY ALL OF THE ORGANIZATION'S ASSETS; III) WINDING UP, DISSOLVING OR LIQUIDATING THE ORGANIZATION; IV) MERGING WITH ONE OR MORE OTHER ENTITIES; OR V) CONSOLIDATING WITH ONE OR MORE OTHER ENTITIES. IN ADDITION, THE GOVERNING DOCUMENTS ALSO REQUIRE APPROVAL BY 100% OF ALL OF THE GOVERNING MEMBERS FOR CERTAIN ACTIONS INCLUDING: I) CHANGING CERTAIN TERMS OF CREDIT AGREEMENTS; AND II) ALTERING CERTAIN TERMS OF MASTER MINIMUM VIABLE VOLUME AGREEMENTS TO BENEFIT ONE MEMBER. FORM 990, PART VI, SECTION A, LINE 8B THERE IS NO COMMITTEE WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS THE FORM 990 PRIOR TO FILING. CIVICA ALSO SENDS A COPY OF FORM 990 TO OUTSIDE TAX COUNSEL AND OTHER MEMBERS OF THE BOARD OF DIRECTORS FOR REVIEW. FORM 990, PART VI, SECTION B, LINE 12C DIRECTORS AND OFFICERS HAVE BEEN PROVIDED TRAINING ON THE CONFLICT OF INTEREST POLICY AND PROCESS, ARE SURVEYED FOR POSSIBLE CONFLICTS OF INTEREST, AND REQUIRED TO DISCLOSE POTENTIAL CONFLICTS ON AN ANNUAL BASIS. THE ANNUAL CONFLICT OF INTEREST DISCLOSURES ARE COLLECTED AND REVIEWED BY GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER. IF A CONFLICT IS IDENTIFIED, THE INDIVIDUAL WITH THE CONFLICT OF INTEREST WILL NOT PARTICIPATE IN THE DELIBERATIVE DISCUSSION OR VOTE ON THE TRANSACTION INVOLVED. FORM 990, PART VI, SECTION B, LINE 15 CIVICA, INC.'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS THE COMPENSATION OF EXECUTIVE STAFF AND OTHER STAFF ON AN ANNUAL BASIS. IN DECEMBER OF 2022, CIVICA, INC. CONDUCTED AN INDEPENDENT COMPENSATION BENCHMARKING STUDY TO ASSESS ITS CURRENT COMPENSATION STRUCTURE AND LEVELS AGAINST THE INDUSTRY PEERS. THE COMPENSATION COMMITTEE USED THIS STUDY AS PART OF THEIR REVIEW PROCESS TO DETERMINE COMPENSATION LEVELS FOR 2024. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS WILL BE MADE AVAILABLE UPON REQUEST. THE FORM 990 IS AVAILABLE THROUGH THE IRS AND OTHER PUBLIC DISCLOSURE WEBSITES. FORM 990, PART VII: ALL EMPLOYEE COMPENSATION IS PAID BY THE REPORTING ORGANIZATION. THE TOTAL COMPENSATION IS THEN ALLOCATED TO THE VARIOUS RELATED ENTITIES BASED UPON THE PERCENT OF TIME THE OFFICERS SPEND ON EACH OF THE ENTITIES. THE COMPENSATION REPORTED IN PART VII REFLECTS THESE ALLOCATIONS VERSUS THE W-2 REPORTING. FORM 990, PART IX, LINE 11G PURCHASED SERVICES: PROGRAM SERVICE EXPENSES 9,199,430. MANAGEMENT AND GENERAL EXPENSES 2,163,236. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 11,362,666. FORM 990, PART I, LINE 5, PART V, LINE 2A, PART VII AND PART IX: CIVICA, INC. IS THE EMPLOYEE OF RECORD AND EMPLOYS A PROFESSIONAL EMPLOYER ORGANIZATION TO PROCESS EMPLOYEE WAGES, WITHHOLDINGS, AND PAYROLL TAXES. CIVICA FOUNDATION 2912 W EXECUTIVE PARKWAY LEHI UT 84043 844514428 FUNDRAISING DE 501(C)(3) 10 CIVICA INC 1 CIVICASCRIPT LLC 2912 W EXECUTIVE PKWY STE 325 LEHI UT 84043 844777602 PHARMACEUTICALS UT N/A C 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 CIVICA FOUNDATION C 27923957 CASH PAID